## 3 Results  
rs10204525 for _PDCD1_ gene and rs550675 for _COL9A1_ gene were genotyped in 45 psoriasis patients and 43 controls. Two of the patient group blood samples could not be used to determine rs10204525 due to sample quality, being excluded from statistical analysis of this genotype. Based on the inclusion criteria, 26 women and 19 men with psoriasis were recruited. Average PASI score was 14.42 (minimum = 2, maximum = 30) and mean DLQI was 11.62 (minimum = 0, maximum = 30). The minimum PASI score and DLQI belonged to patients on biologic therapy for more than six months. The biologic therapies used to treat patients were as follows: anti TNF-\(\alpha\) (Adalimumab for 2 patients with plaque psoriasis, Etancercept for 1 patient with plaque psoriasis), anti IL-12/23 (Ustekinumab for 2 patients with arthropathic psoriasis), anti IL-23 (Guselkumab for 1 patient with plaque psoriasis, Risankizumab for 1 patient with palmolantar psoriasis) and anti IL-17 (Secukinumab for1 patient with arthropathtic psoriasis). Patients were divided according to psoriaticiate disease severity, clinical forms of disease, special areas affected, ongoing treatment and associated comorbidities. The patient profile can be found in Table 1.  
The distribution of the two genes and alleles was according to the Hardy-Weinberg Equilibrium (HWE). For COL9A1 gene variant rs550675, the C/T alleles were evaluated by comparison between the control group and the patient group, but also between the patients, taking into account different parameters. Comparisons between allele frequency and the genotypes between the control group and patient group were performed by Chi-squared test, and the statistical significance is presented by \(p\)-value and shown in Table 2.  
The rank of C/T alleles for rs550675 (\(COL9A1\) gene) has statistically significant values in the psoriatic patient group (\(p\) = 0.026), while the G/A alleles for rs10204525 (\(PDCD1\) gene) show no changes between the two groups (\(p\) = 0.450). The analysis of rs550675 and rs10204525 is shown in Table 3. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline  & \multicolumn{2}{c}{**Sporiasis Type**} & \multicolumn{2}{c}{**Plaque Sporiasis**} & \multicolumn{2}{c}{**Palmoplantar Sporiasis**} & \multicolumn{2}{c}{**Arthropathtic**} \\ \hline \multirow{2}{*}{\begin{tabular}{c} Psoriasis severity \\ (PASI average) \\ \end{tabular} } & Mild psoriasis & 8 (28.5\%) & 7 (70\%) & 3 (42.8\%) \\ \cline{2-6}  & Moderate-severe psoriasis & 20 (71.4\%) & 3 (30\%) & 4 (57.1\%) \\ \hline \multirow{2}{*}{\begin{tabular}{c} DLQ average \\ \end{tabular} } & Mild psoriasis & 10.3 & 10.8 & 4 \\ \cline{2-6}  & Moderate-severe psoriasis & 13.7 & 11.6 & 10.5 \\ \hline \multirow{2}{*}{\begin{tabular}{c} Special areas affected \\ \end{tabular} } & Scalp & 8 (28.5\%) & 0 & 3 (42.8\%) \\ \cline{2-6}  & Nails & 5 (17.8\%) & 6 (60\%) & 0 \\ \hline \multirow{4}{*}{\
\begin{tabular}{c} Comorbidities \\ \end{tabular} } & Cardiovascular diseases & 16 (57.1\%) & 7 (70\%) & 5 (71.4\%) \\ \cline{2-6}  & Pulmonary diseases & 4 (14.2\%) & 2 (20\%) & 2 (28.5\%) \\ \cline{2-6}  & Diabetes mellitus & 6 (21.4\%) & 2 (20\%) & 2 (28.5\%) \\ \cline{2-6}  & Obesity & 8 (28.5\%) & 4 (40\%) & 4 (57.1\%) \\ \cline{2-6}  & Non-alcoholic steatohepatitisitis & 7 (25\%) & 6 (60\%) & 2 (28.5\%) \\ \hline \multirow{4}{*}{
\begin{tabular}{c} Treatment \\ \end{tabular} } & Topical therapies & 17 (60.7\%) & 9 (90\%) & 3 (42.8\%) \\ \cline{2-6}  & Conventional Systemic treatment & 3 (10.7\%) & 0 & 0 \\ \cline{1-1} \cline{2-6}  & Phototherapy & 4 (14.2\%) & 0 & 0 \\ \cline{1-1} \cline{2-6}  & Biological therapy & 4 (14.2\%) & 1 (10\%) & 4 (57.1\%) \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Characteristics of patients included in the study.